UroGen Pharma Ltd. (URGN): Cash & Equivalents
$110.75M
As of 2025-12-31
$79.13M
As of 2026-06-30
+26.0%
3-year compound annual growth
+15.9%
5-year compound annual growth
+19.9%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $110.75M | -35.6% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $171.99M | +81.0% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $95.00M | +71.5% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $55.41M | +24.9% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $44.36M | -16.1% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $52.86M | +6.4% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $49.69M | -51.0% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $101.32M | +173.8% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $37.00M | +73.2% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $21.36M | +18.8% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $17.98M | n/a | 2018-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $110.75M | -35.6% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $62.41M | +84.7% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $41.16M | -37.7% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $37.07M | +213.8% |
| Xencor Inc (XNCR) | 2025-12-31 | $54.07M | +32.3% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $154.97M | -0.3% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.27M | -2.3% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $122.52M | +29.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
Compare URGN, ZVRA, ZYME, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗